Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

612 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations.
Nogami K, Shima M, Fukutake K, Fujii T, Taki M, Matsushita T, Higasa S, Sato T, Sakai M, Arai M, Uchikawa H, Engl W, Abbuehl B, Konkle BA. Nogami K, et al. Among authors: taki m. Int J Hematol. 2017 Nov;106(5):704-710. doi: 10.1007/s12185-017-2265-6. Epub 2017 May 26. Int J Hematol. 2017. PMID: 28550352 Clinical Trial.
Correction to: Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations.
Nogami K, Shima M, Fukutake K, Fujii T, Taki M, Matsushita T, Higasa S, Sato T, Sakai M, Arai M, Uchikawa H, Engl W, Abbuehl B, Konkle BA. Nogami K, et al. Among authors: taki m. Int J Hematol. 2018 Jan;107(1):123-124. doi: 10.1007/s12185-017-2369-z. Int J Hematol. 2018. PMID: 29149425
Inhibitor development, safety and efficacy of Advate® among previously treated patients with hemophilia A in a postmarketing surveillance in Japan.
Fukutake K, Taki M, Matsushita T, Nogami K, Shima M, Yoshioka A, Takamatsu J, Uchikawa H, Takagi H, Arai M, Engl W, Shirahata A. Fukutake K, et al. Among authors: taki m. Int J Hematol. 2019 Mar;109(3):336-345. doi: 10.1007/s12185-018-02574-x. Epub 2019 Jan 2. Int J Hematol. 2019. PMID: 30604312 Clinical Trial.
Spectrum of F8 Genotype and Genetic Impact on Inhibitor Development in Patients with Hemophilia A from Multicenter Cohort Studies (J-HIS) in Japan.
Shinozawa K, Yada K, Kojima T, Nogami K, Taki M, Fukutake K, Yoshioka A, Shirahata A, Shima M; study group on JAPAN HEMOPHILIA INHIBITOR STUDY (J-HIS). Shinozawa K, et al. Among authors: taki m. Thromb Haemost. 2021 May;121(5):603-615. doi: 10.1055/s-0040-1721385. Epub 2020 Nov 30. Thromb Haemost. 2021. PMID: 33254277
Clinical conditions and risk factors for inhibitor-development in patients with haemophilia: A decade-long prospective cohort study in Japan, J-HIS2 (Japan Hemophilia Inhibitor Study 2).
Nogami K, Taki M, Matsushita T, Kojima T, Oka T, Ohga S, Kawakami K, Sakai M, Suzuki T, Higasa S, Horikoshi Y, Shinozawa K, Tamura S, Yada K, Imaizumi M, Ohtsuka Y, Iwasaki F, Kobayashi M, Takamatsu J, Takedani H, Nakadate H, Matsuo Y, Matsumoto T, Fujii T, Fukutake K, Shirahata A, Yoshioka A, Shima M; J-HIS2 study group. Nogami K, et al. Among authors: taki m. Haemophilia. 2022 Sep;28(5):745-759. doi: 10.1111/hae.14602. Epub 2022 Jun 11. Haemophilia. 2022. PMID: 35689832
The International Immune Tolerance Induction Study and its follow-up study on Japanese hemophilia A patients with inhibitors.
Yoshioka A, Ishii E, Ueno T, Usami I, Kobayashi M, Kobayashi R, Sotomatsu M, Shirahata A, Suzuki T, Taki M, Ishida Y, Matsushita T, Shima M, Nogami K, Sakai M, Kigasawa H, Fukutake K. Yoshioka A, et al. Among authors: taki m. Int J Hematol. 2015 Apr;101(4):362-8. doi: 10.1007/s12185-015-1734-z. Epub 2015 Feb 18. Int J Hematol. 2015. PMID: 25690486
612 results